Christian P. Mclean

Array ( [id] => 18181736 [patent_doc_number] => 20230042465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => Manufacturing Methods for Producing Anti-TNF Antibody Compositions [patent_app_type] => utility [patent_app_number] => 17/860416 [patent_app_country] => US [patent_app_date] => 2022-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50965 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17860416 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484982 [patent_doc_number] => 20230212297 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => BISPECIFIC FC MOLECULES [patent_app_type] => utility [patent_app_number] => 17/697632 [patent_app_country] => US [patent_app_date] => 2022-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17697632 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19921107 [patent_doc_number] => 12295362 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-13 [patent_title] => Formulations and processes for CAR T cell drug products [patent_app_type] => utility [patent_app_number] => 17/592105 [patent_app_country] => US [patent_app_date] => 2022-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 13350 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17592105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399618 [patent_doc_number] => 20220041708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain [patent_app_type] => utility [patent_app_number] => 17/510798 [patent_app_country] => US [patent_app_date] => 2021-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17510798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830879 [patent_doc_number] => 20230399404 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => SUSTAINED ANTIBODY AND IMMUNOTHERAPEUTIC DELIVERY TO CERVICAL LYMPH NODES [patent_app_type] => utility [patent_app_number] => 18/249314 [patent_app_country] => US [patent_app_date] => 2021-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11414 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18249314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034199 [patent_doc_number] => 20240084014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO PD-L1 [patent_app_type] => utility [patent_app_number] => 18/249221 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24174 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18249221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034199 [patent_doc_number] => 20240084014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO PD-L1 [patent_app_type] => utility [patent_app_number] => 18/249221 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24174 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18249221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861946 [patent_doc_number] => 20230416382 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => ANTI-C-C CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/248979 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861946 [patent_doc_number] => 20230416382 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => ANTI-C-C CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/248979 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19075302 [patent_doc_number] => 11944645 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-02 [patent_title] => Modified cell and use thereof in gene and cell therapy [patent_app_type] => utility [patent_app_number] => 17/490582 [patent_app_country] => US [patent_app_date] => 2021-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 68 [patent_no_of_words] => 19746 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17490582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460310 [patent_doc_number] => 20220073615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => MIXTURES OF ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/483630 [patent_app_country] => US [patent_app_date] => 2021-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50473 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17483630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19360881 [patent_doc_number] => 20240262915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => ANTI-TIGIT ANTIBODY AND DOUBLE ANTIBODY AND THEIR APPLICATION [patent_app_type] => utility [patent_app_number] => 18/027493 [patent_app_country] => US [patent_app_date] => 2021-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29971 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18027493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18647899 [patent_doc_number] => 20230293678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => CATIONIC NANOPARTICLE ADJUVANTS [patent_app_type] => utility [patent_app_number] => 18/042276 [patent_app_country] => US [patent_app_date] => 2021-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29117 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18647899 [patent_doc_number] => 20230293678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => CATIONIC NANOPARTICLE ADJUVANTS [patent_app_type] => utility [patent_app_number] => 18/042276 [patent_app_country] => US [patent_app_date] => 2021-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29117 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597273 [patent_doc_number] => 20230272068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => MODULAR ASSEMBLY RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/680468 [patent_app_country] => US [patent_app_date] => 2021-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673084 [patent_doc_number] => 20230310557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => RECOMBINANT IMMUNOTOXIN COMPRISING A RIBOTOXIN OR RNASE [patent_app_type] => utility [patent_app_number] => 18/041770 [patent_app_country] => US [patent_app_date] => 2021-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18041770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17274494 [patent_doc_number] => 20210380692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/402322 [patent_app_country] => US [patent_app_date] => 2021-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80607 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17402322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17536478 [patent_doc_number] => 20220115087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER [patent_app_type] => utility [patent_app_number] => 17/395996 [patent_app_country] => US [patent_app_date] => 2021-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41814 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -79 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17395996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17260039 [patent_doc_number] => 20210373024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => METHODS AND SYSTEMS FOR EVALUATION OF IMMUNE CELL INFILTRATE IN STAGE IV COLORECTAL CANCER [patent_app_type] => utility [patent_app_number] => 17/389910 [patent_app_country] => US [patent_app_date] => 2021-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19814 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17389910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865464 [patent_doc_number] => 20220288199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers [patent_app_type] => utility [patent_app_number] => 17/380251 [patent_app_country] => US [patent_app_date] => 2021-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79350 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -101 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17380251 [rel_patent_id] =>[rel_patent_doc_number] =>)